NRx Pharmaceuticals, Inc.
NRXP
$2.75
$0.124.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.85% | -3.81% | -5.00% | -28.11% | -36.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.24% | -27.73% | -28.58% | -38.08% | -36.10% |
| Operating Income | 39.24% | 27.73% | 28.58% | 38.08% | 36.10% |
| Income Before Tax | -36.16% | 5.96% | 16.66% | 43.48% | 36.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.16% | 5.96% | 16.66% | 43.48% | 36.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.16% | 5.96% | 16.66% | 43.48% | 36.49% |
| EBIT | 39.24% | 27.73% | 28.58% | 38.08% | 36.10% |
| EBITDA | 39.25% | 27.74% | 28.58% | 38.09% | 36.10% |
| EPS Basic | 20.27% | 38.37% | 42.43% | 57.64% | 51.97% |
| Normalized Basic EPS | 34.95% | 39.19% | 38.94% | 50.90% | 49.10% |
| EPS Diluted | 20.27% | 38.74% | 42.70% | 57.80% | 52.13% |
| Normalized Diluted EPS | 34.95% | 39.19% | 38.94% | 50.90% | 49.10% |
| Average Basic Shares Outstanding | 61.55% | 54.60% | 40.88% | 33.33% | 30.71% |
| Average Diluted Shares Outstanding | 61.55% | 54.60% | 40.88% | 33.33% | 30.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |